BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21145740)

  • 1. Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.
    Ray P; Wright J; Adam J; Bennett J; Boucharens S; Black D; Cook A; Brown AR; Epemolu O; Fletcher D; Haunso A; Huggett M; Jones P; Laats S; Lyons A; Mestres J; de Man J; Morphy R; Rankovic Z; Sherborne B; Sherry L; van Straten N; Westwood P; Zaman GZ
    Bioorg Med Chem Lett; 2011 Jan; 21(1):97-101. PubMed ID: 21145740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 3, aryl substituted pyrrolidines.
    Bosanac T; Hickey ER; Ginn J; Kashem M; Kerr S; Kugler S; Li X; Olague A; Schlyer S; Young ER
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3746-9. PubMed ID: 20471253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimisation of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors.
    Ray P; Wright J; Adam J; Boucharens S; Black D; Brown AR; Epemolu O; Fletcher D; Huggett M; Jones P; Laats S; Lyons A; de Man J; Morphy R; Sherborne B; Sherry L; Straten Nv; Westwood P; York M
    Bioorg Med Chem Lett; 2011 Feb; 21(4):1084-8. PubMed ID: 21251828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: potent and selective p70S6 kinase inhibitors.
    Bandarage U; Hare B; Parsons J; Pham L; Marhefka C; Bemis G; Tang Q; Moody CS; Rodems S; Shah S; Adams C; Bravo J; Charonnet E; Savic V; Come JH; Green J
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5191-4. PubMed ID: 19632115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triazine and pyrimidine based ROCK inhibitors with efficacy in spontaneous hypertensive rat model.
    Ho KK; Beasley JR; Belanger L; Black D; Chan JH; Dunn D; Hu B; Klon A; Kultgen SG; Ohlmeyer M; Parlato SM; Ray PC; Pham Q; Rong Y; Roughton AL; Walker TL; Wright J; Xu K; Xu Y; Zhang L; Webb M
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6027-31. PubMed ID: 19800787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account.
    Wu F; Büttner FH; Chen R; Hickey E; Jakes S; Kaplita P; Kashem MA; Kerr S; Kugler S; Paw Z; Prokopowicz A; Shih CK; Snow R; Young E; Cywin CL
    Bioorg Med Chem Lett; 2010 Jun; 20(11):3235-9. PubMed ID: 20462760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of the tyrosine kinase EphB4. Part 4: Discovery and optimization of a benzylic alcohol series.
    Barlaam B; Ducray R; Lambert-van der Brempt C; Plé P; Bardelle C; Brooks N; Coleman T; Cross D; Kettle JG; Read J
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2207-11. PubMed ID: 21441027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors.
    Fang X; Chen YT; Sessions EH; Chowdhury S; Vojkovsky T; Yin Y; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; LoGrasso P; Bannister TD; Feng Y
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1844-8. PubMed ID: 21349713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benzothiazoles as Rho-associated kinase (ROCK-II) inhibitors.
    Yin Y; Lin L; Ruiz C; Cameron MD; Pocas J; Grant W; Schröter T; Chen W; Duckett D; Schürer S; Lograsso P; Feng Y
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6686-90. PubMed ID: 19837589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: part 2, optimization for blood pressure reduction in spontaneously hypertensive rats.
    Ginn JD; Bosanac T; Chen R; Cywin C; Hickey E; Kashem M; Kerr S; Kugler S; Li X; Prokopowicz A; Schlyer S; Smith JD; Turner MR; Wu F; Young ER
    Bioorg Med Chem Lett; 2010 Sep; 20(17):5153-6. PubMed ID: 20678931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.
    Morwick T; Büttner FH; Cywin CL; Dahmann G; Hickey E; Jakes S; Kaplita P; Kashem MA; Kerr S; Kugler S; Mao W; Marshall D; Paw Z; Shih CK; Wu F; Young E
    J Med Chem; 2010 Jan; 53(2):759-77. PubMed ID: 20000469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules.
    Andrews PD; Becroft M; Aspegren A; Gilmour J; James MJ; McRae S; Kime R; Allcock RW; Abraham A; Jiang Z; Strehl R; Mountford JC; Milligan G; Houslay MD; Adams DR; Frearson JA
    Biochem J; 2010 Nov; 432(1):21-33. PubMed ID: 20854259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cortistatin A is a high-affinity ligand of protein kinases ROCK, CDK8, and CDK11.
    Cee VJ; Chen DY; Lee MR; Nicolaou KC
    Angew Chem Int Ed Engl; 2009; 48(47):8952-7. PubMed ID: 19844931
    [No Abstract]   [Full Text] [Related]  

  • 14. Tetrahydroisoquinoline derivatives as highly selective and potent Rho kinase inhibitors.
    Fang X; Yin Y; Chen YT; Yao L; Wang B; Cameron MD; Lin L; Khan S; Ruiz C; Schröter T; Grant W; Weiser A; Pocas J; Pachori A; Schürer S; Lograsso P; Feng Y
    J Med Chem; 2010 Aug; 53(15):5727-37. PubMed ID: 20684608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics.
    Zeng Q; Bourbeau MP; Wohlhieter GE; Yao G; Monenschein H; Rider JT; Lee MR; Zhang S; Lofgren J; Freeman D; Li C; Tominey E; Huang X; Hoffman D; Yamane H; Tasker AS; Dominguez C; Viswanadhan VN; Hungate R; Zhang X
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1652-6. PubMed ID: 20137932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of 4-aryl-5-aminoalkyl-thiazole-2-amines derivatives as ROCK II inhibitors.
    Ma S; Wang L; Ouyang B; Fan M; Qi J; Yao L
    Bioorg Med Chem; 2020 Oct; 28(19):115683. PubMed ID: 32912437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of virtual screening with high-throughput screening for the identification of novel Rho-kinase I inhibitors.
    Gong LL; Fang LH; Peng JH; Liu AL; Du GH
    J Biotechnol; 2010 Feb; 145(3):295-303. PubMed ID: 19963024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 2: improvement of potency in vitro and in vivo.
    Shimizu H; Yasumatsu I; Hamada T; Yoneda Y; Yamasaki T; Tanaka S; Toki T; Yokoyama M; Morishita K; Iimura S
    Bioorg Med Chem Lett; 2011 Feb; 21(3):904-8. PubMed ID: 21232950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the structure of adenosine mimic of bisubstrate-analog inhibitors on their activity towards basophilic protein kinases.
    Enkvist E; Kriisa M; Roben M; Kadak G; Raidaru G; Uri A
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6098-101. PubMed ID: 19800227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of potential Rho-kinase inhibitors based on the chemistry of an original heterocycle: 4,4-dimethyl-3,4-dihydro-1H-quinolin-2-one.
    Letellier MA; Guillard J; Caignard DH; Ferry G; Boutin JA; Viaud-Massuard MC
    Eur J Med Chem; 2008 Aug; 43(8):1730-6. PubMed ID: 18164518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.